Bristol Myers Squibb Secures Canadian Regulatory Nod For Lung Cancer Candidate In Neoadjuvant Setting
Health Canada announced approval for Bristol Myers Squibb’s (NASDAQ: BMY) OPDIVO (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles in adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setti
